Skip to main content
. 2019 Apr 12;2(4):e190819. doi: 10.1001/jamanetworkopen.2019.0819

Figure 1. CONSORT Diagram of the Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial.

Figure 1.

HSIL indicates high-grade squamous intraepithelial lesions; 9vHPV, nonavalent human papillomavirus vaccine.